Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Annexon Inc (ANNX)

Annexon Inc (ANNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Annexon's Neuroinflammation Thesis Hinges on Whether GBS Trial Data Translate to Commercial Viability Barchart - Wed Aug 12, 4:01PM CDT

Barchart Research What to Expect from ANNX Earnings ANNX Generated August 12, 2026 Current Price $5.33 EPS Estimate $$-0.23 Consensus Rating Moderate Buy Average Move 5.21% Annexon's Neuroinflammation...

ANNX : 5.34 (+0.19%)
Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones GlobeNewswire - Wed Aug 12, 5:05AM CDT

Rapid, Positive Clinical Outcomes in GBS FORWARD Study Reinforce Consistency and Reproducibility of Tanruprubart Treatment Effect Demonstrated in Phase 3 and Real-World Evidence Studies; BLA Submission...

ANNX : 5.34 (+0.19%)
Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study GlobeNewswire - Wed Aug 12, 5:00AM CDT

BRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory...

ANNX : 5.34 (+0.19%)
Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors GlobeNewswire - Mon Aug 10, 3:05PM CDT

BRISBANE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory...

ANNX : 5.34 (+0.19%)
Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week GlobeNewswire - Thu Aug 6, 7:00AM CDT

Early Outcomes Reinforce the Consistency and Reproducibility of Tanruprubart Treatment Effect Previously Demonstrated in Phase 3 and Real-World Evidence Studies  Potential to Become the First Approved...

ANNX : 5.34 (+0.19%)
Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance GlobeNewswire - Thu Jul 30, 3:01PM CDT

BRISBANE, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory...

ANNX : 5.34 (+0.19%)
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Thu Jul 16, 3:05PM CDT

BRISBANE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory...

ANNX : 5.34 (+0.19%)
Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026 GlobeNewswire - Tue Jul 14, 3:05PM CDT

BRISBANE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory...

ANNX : 5.34 (+0.19%)
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Tue Jun 16, 3:05PM CDT

BRISBANE, Calif., June 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory...

ANNX : 5.34 (+0.19%)
MarketBeat.com
Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout MarketBeat - Thu Jun 4, 2:07AM CDT

Annexon (NASDAQ:ANNX) executives outlined a series of expected clinical and regulatory updates across the company’s complement-focused pipeline during a session at the Jefferies Conference, highlighting...

ANNX : 5.34 (+0.19%)

Barchart Exclusives

Quantinuum’s Cloud Deal With Oracle Sends Clear Message on Hybrid AI Barchart - 11 minutes ago
Quantinuum is putting its Helios quantum computer inside Oracle Cloud, pairing quantum power with AI as revenue and bookings surge in Q2. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.